Mayo Clinic Pharmacy Grand Rounds

How Low Should LDL-C Go? The Role of Non-Statin Therapy in Management of Blood Cholesterol

Hannah Poppen, PharmD (@PoppenPharmD) reviews guideline recommendations for management of blood cholesterol, describes the risks and benefits associated with adjunct non-statin therapy and identifies patient-specific characteristics in which PCSK9 inhibitor therapy should be considered.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

TEG My Word for It: A New Approach for Interpreting Coagulation

Nicholas Vollmer, PharmD (@VollmerNick) describes the mechanism through which thromboelastography works and how it differs from current assessments of coagulation, identifies patient scenarios where thromboelastography may be of benefit compared to standard of care and discovers barriers of widespread use of thromboelastography.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Antibody-Mediated Rejection: Challenges and Treatment Options

Yen Tran, PharmD, MBA (@YenTranlt) illustrates the consequences of antibody mediated rejection (AMR) on solid organ transplant recipients, develops a management strategy for AMR and outlines approaches to AMR management.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

The GIST of It: Treatment of Gastrointestinal Stromal Tumors

Mikhaila Rice, PharmD, BCPS (@MikhailaPharmD) reviews pathophysiology of gastrointestinal stromal tumors, describes the pharmacology of medications used to treat gastrointestinal stromal tumors and discusses the place in therapy of new treatment options, including ripretinib and avapritinib.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Wait a Second! Aspirin for Secondary Prevention in Patients with CAD and Atrial Fibrillation

Laurel Lake, PharmD (@laurel_pharmd) outlines the guideline recommendations for duration of antiplatelet therapy in acute coronary syndrome in patients using anticoagulation for atrial fibrillation, reviews recent literature examining antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease and discusses the balance of risks and benefits of antiplatelet and anticoagulant agents in these patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

To Be or Not to Be: Benefits and Challenges of 340B

Dylan Kosaski, PharmD (@Dylan_Kosaski) identifies the purpose of 340B and the impact on health care costs, evaluates the role of 340B contract pharmacies and reviews challenges facing the 340B program and potential consequences.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Giving It Our Best Shot: Pharmacy-Driven Initiatives to Enhance COVID-19 Immunization Efforts

Kellyn Engstrom, PharmD, MPH (@KellynEPharmD) lists three differences between COVID-19 immunization efforts and previous mass immunization strategies, describes challenges in complying with vaccine delivery, storage, and administration processes required by FDA emergency use authorization and summarizes the current state and future directions of COVID-19 mass immunization efforts.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Going Viral: The Role of Remdesivir in COVID-19

Jennifer Adema, PharmD, MBA (@JAdemaPharmD) describes remdesivir’s mechanism of action against SARS-CoV-2, identifies optimal adult patient populations for remdesivir and outlines future directions for remdesivir in COVID-19 treatment.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Better Cef than Sorry: Beta-Lactam Monitoring in the ICU

Andrew Webb, Pharm.D. (@AJWPharm) describes the pharmacokinetic alterations of critical illness and the implications for beta-lactam optimization, recognizes the potential role of beta-lactam therapeutic monitoring in predicting drug effectiveness, and identifies the potential role of beta-lactam therapeutic monitoring in recognizing drug toxicity.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Is it O-K+?

Hannah Brokmeier, Pharm.D. (@hannahbrokmeier) discusses the role of MRAs in patients with ESRD, reviews the literature concerning risks and benefits of MRAs in patients with ESRD, and outlines a potential MRA treatment regimen for a patient with dialysis-dependent ESRD.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.